Abstract
1955 Primary systemic therapy by dual HER2 blockage with lapatinib (La) + trastuzumab (T) for Japanese patients (pts) with HER2+ breast cancer (BC): Association of La toxicity and dose with treatment efficacy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have